Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%

Total mortality · adults with primary hypertension

First‐line beta‐blocker showed no clear difference in total mortality compared with placebo (moderate certainty).

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
RR 0.96 [0.86, 1.07]
5 studies · 19313 participants
Moderate

Stroke · adults with primary hypertension

First‐line beta‐blocker may leads to lower total stroke compared with placebo (low certainty).

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
RR 0.83 [0.72, 0.97]
5 studies · 19313 participants
Low

Total coronary heart disease · adults with primary hypertension

First‐line beta‐blocker showed no clear difference in total coronary heart disease compared with placebo (low certainty).

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
RR 0.9 [0.78, 1.03]
5 studies · 19313 participants
Low

Cardiovascular events · adults with primary hypertension

First‐line beta‐blocker may leads to lower total cardiovascular events compared with placebo (low certainty).

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
RR 0.89 [0.81, 0.98]
5 studies · 19313 participants
Low

Withdrawals due to adverse events · adults with primary hypertension

First‐line beta‐blocker may leads to higher withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

First‐line drugs for hypertension 2018 · Cochrane Headline outcomes only
RR 4.59 [4.11, 5.13]
4 studies · 18565 participants
Low